Castle Biosciences Inc., a company focused on improving health through innovative tests, announced the approval of new compensation terms involving restricted stock units (RSUs) for 66 employees. On June 14, 2025, the Compensation Committee of the Board of Directors granted RSUs covering a total of 135,978 shares of common stock as part of the company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in three equal annual installments, contingent on continued employment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。